摘要
目的观察阿加曲班对肺动脉栓塞(PE)患者抗凝疗效及安全性。方法 4例PE合并下肢深静脉血栓形成(DVT)患者,均经CT肺动脉造影(CTPA)及下肢深静脉加压彩超(CUS)检查确诊,给予阿加曲班治疗20 mg/d,治疗8~12天。后续给予低分子肝素钙4100IU,2~6天,再改为口服抗凝药利伐沙班或华法林,共3个月。结果 4例患者使用阿加曲班后,行CTPA检查提示肺动脉血栓大部分溶解吸收,CUS检查下肢DVT的血管完全和部分再通。临床症状明显缓解,无出血、血小板减少并发症。随访3~6个月,无PE及DVT复发症状。结论阿加曲班可作为临床治疗PE安全有效的抗凝手段。
Objective To observe the anticoagulant effects and safety of argatroban in the treatment of patients with pulmonary embolism (PE). Methods Four patients with PE complicated with deep venous thrombosis(DVT), who confirmed by computed tomographic pulmonary angiography(CTPA) and compression venous ultrasonography(CUS),were treated with argatroban (20 mg/d) for 8~12 days, and then, low molecular heparin calcium( 4100 IU) for 2~6 days .Thereafter, oral anticoagulant, such as Rivaroxaban or Warfarin, would be taken for 3 months. Results The clinical symptoms were all relieved apparently after argatroban therapy. CTPA scan indicated that most thrombus dissolved without bleeding and thrombocytopenia. And CUS showed complete and partial recanalization in lesion veins. No PE or DVT recurred during the follow-up with a time of 3~6 months. Conclusion Argatroban can be a safe and effective anticoagulant therapy for PE.
出处
《中国血管外科杂志（电子版）》
2014年第1期34-37,共4页
Chinese Journal of Vascular Surgery(Electronic Version)
关键词
阿加曲班
肺动脉栓塞
抗凝治疗
Argatroban
Pulmonary embolism
Anticoagulant therapy
